Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00318474 · ClinicalTrials.gov registry record · Phase 3
Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy
A Phase 3 study, sponsored by St. Joseph's Hospital and Medical Center, Phoenix.
- Terminated
- Registry status
- Phase 3
- Development phase
- 184
- Enrollment target
NCT00318474: Clinical Trial Phase 3 study, sponsored by St. Joseph's Hospital and Medical Center, Phoenix.
NCT00318474 is a Phase 3 study that was terminated before completion, run by St. Joseph's Hospital and Medical Center, Phoenix. The registered enrollment target is 184 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (76% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00318474, a Phase 3 study, was terminated before completion, sponsored by St. Joseph's Hospital and Medical Center, Phoenix.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 184 participants
- Enrollment target
Study Summary
IgA nephropathy (IgAN) is the most common type of glomerulonephritis worldwide. 15-40% of individuals diagnosed with IgAN, including children, will eventually progress to chronic renal insufficiency (CRI) and end stage renal disease (ESRD). The study is to evaluate the safety and benefits of MMF in patients with IgAN who have been pre-treated (and continue to be treated) with angiotensin converting enzyme inhibitors (ACEi) and fish oil supplements (FOS).
Primary Outcome
Urine protein/creatinine ratio after 6 months treatment with MMF or placebo.
Interventions
- DRUG Mycophenolate Mofetil (MMF)
- DRUG MMF Placebo
- DRUG ACEi
- DRUG FOS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2002-01 |
| Est. Completion | 2010-03 |
| Phase | Phase 3 |
Why NCT00318474 stopped before completion
NCT00318474 is an interventional study that assigns participants to a tested intervention. The registered 184 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (76% lower).
The record links to 0 conditions, and to 4 interventions - of which Mycophenolate Mofetil (MMF) is the first listed.
NCT00318474 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00318474 about?
NCT00318474 is a clinical study titled "Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy". IgA nephropathy (IgAN) is the most common type of glomerulonephritis worldwide. 15-40% of individuals diagnosed with IgAN, including children, will eventually progress to chronic renal insufficiency (CRI) and end stage renal disease (ESRD). The study is to evaluate the safety and benefits of MMF in ...
What is the current status of trial NCT00318474?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 184 participants. The study started on 2002-01. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00318474?
The interventions under investigation include: Mycophenolate Mofetil (MMF) (DRUG), MMF Placebo (DRUG), ACEi (DRUG), FOS (DRUG).
Who is sponsoring clinical trial NCT00318474?
This trial is sponsored by St. Joseph's Hospital and Medical Center, Phoenix, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00318474's enrollment target sits among peer trials
184 1418th of 2000 higher than 581 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03903510 · 184 participants · NA
Virtual Reality During Pediatric Cast Removal
- NCT04020510 · 184 participants · Phase 4
Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder
- NCT04135846 · 184 participants · Phase 2
Alpha-1 Blockade for Alcohol Use Disorder (AUD)
- NCT04396873 · 184 participants · Phase 1
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia